Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Amino Acids Mixture,Minerals,Vitamins
Therapeutic Area : Genetic Disease
Study Phase : Approved
Sponsor : Relief Therapeutics
Deal Size : $72.2 million
Deal Type : Acquisition
Details : Acquisition further diversifies Relief's pipeline with both commercial products and clinical-stage programs and provides a commercial infrastructure foundation for future product launches.
Brand Name : PKU Golike
Molecule Type : Small molecule
Upfront Cash : $23.3 million
June 29, 2021
Lead Product(s) : Amino Acids Mixture,Minerals,Vitamins
Therapeutic Area : Genetic Disease
Highest Development Status : Approved
Sponsor : Relief Therapeutics
Deal Size : $72.2 million
Deal Type : Acquisition
Lead Product(s) : APR-OD031
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Grants Orphan Drug Designation to APR-OD031 for the Treatment of Phenylketonuria (PKU)
Details : First mix of amino acids having a pharmacological primary mode of action designed to reduce and control Phenylalanine fluctuations.
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Not Applicable
March 26, 2020
Lead Product(s) : APR-OD031
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?